HERON THERAPEUTICS, INC. /DE/·4

Jun 8, 10:27 AM ET

Forbes William P 4

Research Summary

AI-generated summary

Updated

Heron Therapeutics (HRTX) EVP William Forbes Converts 25,000 RSUs

What Happened

  • William P. Forbes, EVP & Chief Development Officer of Heron Therapeutics, converted 25,000 restricted stock units (RSUs) on 2026-06-06. The Form 4 shows 12,500 shares acquired (conversion) and 12,500 shares disposed at $0.00 (derivative). No cash proceeds are reported.

Key Details

  • Transaction date: 2026-06-06; Form filed 2026-06-08 (timely).
  • Transaction code: M (exercise or conversion of a derivative security).
  • Share counts/prices reported: 12,500 shares acquired (price N/A); 12,500 shares disposed at $0.00.
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Footnotes: F1—each RSU converts to one share of common stock; F2—these RSUs vest in four equal annual installments beginning one year after grant, subject to continued service.
  • The filing does not state the reason for the $0.00 disposed line; filings of this form commonly show shares withheld or surrendered to satisfy tax withholding or other obligations, but the footnotes here do not explicitly confirm that.

Context

  • This was a conversion/settlement of RSUs (not an open-market buy or sale). The transaction does not indicate a market sale for cash and therefore does not directly signal a buy or sell sentiment by the insider.